PMID- 35005849
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20220325
IS  - 2052-1707 (Electronic)
IS  - 2052-1707 (Linking)
VI  - 10
IP  - 1
DP  - 2022 Feb
TI  - Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as 
      an add-on therapy to metformin in patients with type 2 diabetes mellitus: A 
      retrospective cohort study in Korea.
PG  - e00910
LID - 10.1002/prp2.910 [doi]
LID - e00910
AB  - Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are antidiabetic drugs with 
      associated safety concerns regarding the risk of genital and urinary tract 
      infections. This study assessed the risk of genital and urinary tract infections 
      associated with prescription of SGLT-2 inhibitors as an add-on therapy to 
      metformin in patients with type 2 diabetes mellitus (T2DM) compared to dipeptidyl 
      peptidase-4 (DPP-4) inhibitors, sulfonylurea (SU), and thiazolidinedione (TZD). 
      We conducted a retrospective cohort study using the NHIS-National Health 
      Insurance-Database in Korea from 2014 to 2017. Patients aged >/=19 years and those 
      diagnosed with T2DM prior to drug prescription were enrolled. The outcomes were 
      genital and urinary tract infections. Analysis was performed using Cox's 
      proportional hazard model following 1:1 propensity score matching to calculate 
      the hazard ratio (HR) with a 95% confidence interval (CI). Among the 107 131 
      patients included in the study, a total of 7738, 7145, and 2175 patients were 
      assigned to the DPP-4 inhibitors, SU, and TZD comparator groups, using the 
      propensity score (PS) of each comparator based on 7741 people in the assessed 
      drug SGLT-2 inhibitor group. SGLT-2 inhibitors were associated with a higher risk 
      of genital infections than DPP-4 inhibitors (HR: 2.39, 95% CI: 2.07-2.76), SU 
      (HR: 3.23, 95% CI: 2.73-3.81), and TZD (HR: 3.23, 95% CI: 2.35-4.44), as an 
      add-on therapy to metformin. Similar results were observed for the risk of 
      urinary tract infections. In conclusion, SGLT-2 inhibitors are significantly 
      associated with a higher risk of genital and urinary tract infections compared to 
      DPP-4 inhibitors, SU, and TZD.
CI  - (c) 2022 The Authors. Pharmacology Research & Perspectives published by British 
      Pharmacological Society and American Society for Pharmacology and Experimental 
      Therapeutics and John Wiley & Sons Ltd.
FAU - Yang, Hyeri
AU  - Yang H
AD  - Department of Drug Safety Information, Korea Institute of Drug Safety and Risk 
      Management, Gyeonggi-do, Republic of Korea.
FAU - Choi, Eunmi
AU  - Choi E
AUID- ORCID: 0000-0002-8486-4222
AD  - Department of Drug Safety Information, Korea Institute of Drug Safety and Risk 
      Management, Gyeonggi-do, Republic of Korea.
FAU - Park, Eunjun
AU  - Park E
AD  - Department of Drug Safety Information, Korea Institute of Drug Safety and Risk 
      Management, Gyeonggi-do, Republic of Korea.
FAU - Na, Eonji
AU  - Na E
AD  - Department of Drug Safety Information, Korea Institute of Drug Safety and Risk 
      Management, Gyeonggi-do, Republic of Korea.
FAU - Chung, Soo Youn
AU  - Chung SY
AD  - Department of Drug Safety Information, Korea Institute of Drug Safety and Risk 
      Management, Gyeonggi-do, Republic of Korea.
FAU - Kim, Bonggi
AU  - Kim B
AUID- ORCID: 0000-0002-0965-1323
AD  - Department of Drug Safety Information, Korea Institute of Drug Safety and Risk 
      Management, Gyeonggi-do, Republic of Korea.
FAU - Han, Soon Young
AU  - Han SY
AD  - Department of Drug Safety Information, Korea Institute of Drug Safety and Risk 
      Management, Gyeonggi-do, Republic of Korea.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Pharmacol Res Perspect
JT  - Pharmacology research & perspectives
JID - 101626369
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/administration & dosage/*adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genital Diseases/epidemiology/etiology
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*adverse effects
MH  - Male
MH  - Metformin/administration & dosage/*adverse effects
MH  - Middle Aged
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Sodium-Glucose Transporter 2 Inhibitors/administration & dosage/*adverse effects
MH  - Urinary Tract Infections/epidemiology/etiology
MH  - Young Adult
PMC - PMC8929338
OTO - NOTNLM
OT  - SGLT-2 inhibitors
OT  - genital infection
OT  - type 2 diabetes mellitus
OT  - urinary tract infection
EDAT- 2022/01/11 06:00
MHDA- 2022/02/25 06:00
PMCR- 2022/01/10
CRDT- 2022/01/10 09:46
PHST- 2021/08/11 00:00 [received]
PHST- 2021/12/18 00:00 [accepted]
PHST- 2022/01/10 09:46 [entrez]
PHST- 2022/01/11 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2022/01/10 00:00 [pmc-release]
AID - PRP2910 [pii]
AID - 10.1002/prp2.910 [doi]
PST - ppublish
SO  - Pharmacol Res Perspect. 2022 Feb;10(1):e00910. doi: 10.1002/prp2.910.